UNIGE document Scientific Article
previous document  unige:86256  next document
add to browser collection

Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies

Di Nisio, Marcello
Vedovati, Maria C
Riera-Mestre, Antoni
Prins, Martin H
Mueller, Katharina
Cohen, Alexander T
Wells, Philip S
Beyer-Westendorf, Jan
show hidden authors show all authors [1 - 16]
Published in Thrombosis and haemostasis. 2016, vol. 116, no. 4
Abstract The pharmacokinetics of oral rivaroxaban are highly predictable and only affected to a limited extent by bodyweight; therefore, dose adjustments for bodyweight are not required. However, this raises concerns among physicians for potential under- or overdosing. This substudy of the randomised EINSTEIN DVT and EINSTEIN PE trials, which compared rivaroxaban with enoxaparin/vitamin K antagonist (VKA) therapy, aimed to determine the incidence of major bleeding in patients with a low bodyweight and recurrent venous thromboembolism (VTE) in patients with a high bodyweight during rivaroxaban or enoxaparin/VKA therapy. More than 8,000 patients with objectively diagnosed deep-vein thrombosis or pulmonary embolism were included. Adjusted hazard ratios for recurrent VTE and bleeding were calculated using the Cox proportional hazards model. Analyses were performed for both the first 21 days of treatment and the whole treatment period. For rivaroxaban recipients, there was no association between bodyweight or body mass index (BMI) and risk of recurrent VTE (ptrend=0.87 and 0.62, respectively), major bleeding (ptrend=0.24 and 0.36, respectively) or clinically relevant bleeding (ptrend=0.17 and 0.63, respectively). Major bleeding events were numerically lower in rivaroxaban patients across all bodyweight and BMI categories. Hazard ratios for rivaroxaban vs enoxaparin/VKA were similar in all bodyweight and BMI categories, both during the first 21 days and the whole treatment period. The fixed-dose rivaroxaban regimen is not associated with an increased risk of major bleeding or recurrent VTE in patients with either a low or high bodyweight. A high BMI was not associated with an increased risk of recurrent VTE during anticoagulation.
PMID: 27535349
Full text
This document has no fulltext available yet, but you can contact its author by using the form below.
Research group La maladie thromboembolique veineuse (808)
(ISO format)
DI NISIO, Marcello et al. Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies. In: Thrombosis and haemostasis, 2016, vol. 116, n° 4. doi: 10.1160/TH16-02-0087 https://archive-ouverte.unige.ch/unige:86256

378 hits

0 download


Deposited on : 2016-08-22

Export document
Format :
Citation style :